The Korean Ministry of Food and Drug Safety has approved three anti-obesity drugs for long-term management in the past decade. In addition, since 2019, bariatric surgery has been financially supported by National Health Insurance Service in Korea. In this review, the mechanisms of action and the clinical implications of the recently approved anti-obesity drugs, lorcaserin, naltrexone/bupropion, and liraglutide are explained. Lorcaserin stimulates proopiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript (CART) neurons and inhibits neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons, which results in the activation of melanocortin 3/4 receptors. Naltrexone/bupropion stimulates POMC neurons through bupropion; this stimulation is augmented by blocking the autoinhibitory mechanism of POMC with naltrexone. The hypophagic effect of liraglutide is mediated through the direct activation of POMC/CART neurons and the indirect suppression of NPY/AgRP neurons through γ-aminobutyric acid-dependent signaling, with adjunctive suppression of the mesolimbic dopamine reward system. In addition to liraglutide, another glucagon-like peptide-1 receptor agonist, semaglutide, is expected to be added to the list of anti-obesity drugs in the near future. In patients with obesity and high cardiovascular risk, lorcaserin was considered neutral and liraglutide was considered favorable, whereas inconclusive results were obtained for naltrexone/bupropion.

Citations

• Phytoactives for Obesity Management: Integrating Nanomedicine for Its Effective Delivery
  Ashok Kumar Mandal, Ankit Sahoo, Waleed H Almalki, Salem Salman Almujri, Abdulrahman Alhamyani, Alhussain Aodah, Nabil K Alruwaili, Sharifah Zamiah Binti Syed Abdul Kadir, Rambha Kumari Mandal, Rami A Almalki, Jonathan A Lal, Mahfoozur Rahman
  Nutrition Reviews.2025; 83(6): 1152.     CrossRef
• Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice
  Ji-Eun Song, Hae-Jin Ko, A-Sol Kim
  Drug Design, Development and Therapy.2024; Volume 18: 845.     CrossRef
• Pharmacological Treatment of Obesity in Older Adults
  Ondřej Žižka, Martin Haluzík, Edward B. Jude
  Drugs & Aging.2024; 41(11): 881.     CrossRef
• 360-Degree Perspectives on Obesity
  Magdalena Cuciureanu, Cătălin-Cezar Caratașu, Levon Gabrielian, Otilia Elena Frăsinariu, Laura Elisabeta Checheriță, Laura Mihaela Trandafir, Gabriela Dumitrița Stanciu, Andrei Szilagyi, Ina Pogonea, Gabriela Bordeianu, Radu Petru Soroceanu, Călin Vasile
  Medicina.2023; 59(6): 1119.     CrossRef
• Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options
  Arturo Cesaro, Gianantonio De Michele, Fabio Fimiani, Vincenzo Acerbo, Gianmaria Scherillo, Giovanni Signore, Francesco Paolo Rotolo, Francesco Scialla, Giuseppe Raucci, Domenico Panico, Felice Gragnano, Elisabetta Moscarella, Olga Scudiero, Cristina Menn
  Frontiers in Cardiovascular Medicine.2023;[Epub]     CrossRef
• AgRP/NPY and POMC neurons in the arcuate nucleus and their potential role in treatment of obesity
  Muhammad Sufyan Vohra, Khaled Benchoula, Christopher J. Serpell, Wong Eng Hwa
  European Journal of Pharmacology.2022; 915: 174611.     CrossRef
• Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis
  Naazneen Arastu, Olivia Cummins, Wanda Uribe, Eric C. Nemec
  International Journal of Clinical Pharmacy.2022; 44(4): 852.     CrossRef
• Pharmacotherapy in obesity: the current state and the near future
  Yoon Jeong Cho, Kyoung-Kon Kim
  Journal of the Korean Medical Association.2022; 65(8): 514.     CrossRef
• FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade
  Zarwa Idrees, Ivan Cancarevic, Li Huang
  Cureus.2022;[Epub]     CrossRef
• Pregnancy outcomes after inadvertent exposure of anti-obesity drugs during pregnancy
  Eun Jeong Choi, Jung Yeol Han
  Clinical and Experimental Obstetrics & Gynecology.2021;[Epub]     CrossRef
• Computational Drug Repurposing Approach to Identify Potential Fatty Acid-Binding Protein-4 Inhibitors to Develop Novel Antiobesity Therapy
  Somdutt Mujwar, Vivek Kumar
  ASSAY and Drug Development Technologies.2020; 18(7): 318.     CrossRef
• Managing obesity through natural polyphenols: A review
  Manisha Singh, Thilini Thrimawithana, Ravi Shukla, Benu Adhikari
  Future Foods.2020; 1-2: 100002.     CrossRef
• Reducing Effect of Farnesylquinone on Lipid Mass in C. elegans by Modulating Lipid Metabolism
  Xihua Jia, Manglin Xu, Aigang Yang, Yan Zhao, Dong Liu, Jian Huang, Peter Proksch, Wenhan Lin
  Marine Drugs.2019; 17(6): 336.     CrossRef
• Mechanisms of action and clinical applications of anti-obesity drugs currently available in Korea
  Kyoung Kon Kim
  Journal of the Korean Medical Association.2019; 62(11): 588.     CrossRef